Abstract
Purpose: To investigate the effectiveness and safety of the combination of Kanglaite injection (KLTi) and gemcitabine and cisplatin (GP) chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).Methods: PubMed, Web of Science, Embase, Cochrane Library, CNKI, Wan-Fang, CBM, and CQVIP were comprehensively searched from January 2010 till November 2020. Randomized controlled trials (RCTs) of KLTi plus GP in the treatment of NSCLC were selected and assessed for inclusion. Review Manager 5.3 software was used for meta-analysis.Results: Twenty-five RCTs on advanced NSCLC examined the inclusion criteria. The meta-analysis showed that compared with GP chemotherapy alone, KLTi plus GP chemotherapy significantly improved objective response rate (ORR) (RR = 1.36, 95% CI 1.23-1.51, p < 0.00001), disease control rate (DCR) (RR = 1.17, 95% CI 1.11 - 1.23, p < 0.00001), and reduced adverse drug reactions(ADRs) such as hair loss (RR = 0.60, 95% CI 0.47 - 0.76, p < 0.0001), gastrointestinal reaction (RR = 0.68, 95% CI 0.62 - 0.75, p < 0.00001), impairment of liver and kidney function (RR = 0.65, 95% CI 0.53 - 0.80, p < 0.001), nervous system damage (RR = 0.42, 95% CI 0.26 - 0.69, p = 0.0005), myelosuppression (I-II phase) (RR = 0.79, 95 % CI 0.66 - 0.95, p = 0.01), myelosuppression (III-IV phase) (RR = 0.44, 95 % CI0.27 - 0.72, p = 0.001), anemia (RR = 0.74, 95 % CI 0.60 - 0.91, p = 0.006), leukopenia (RR = 0.78, 95% CI 0.69, 0.87, p < 0.0001), thrombocytopenia (RR = 0.59, 95 % CI 0.49, 0.72, p < 0.00001), hypochromia (RR = 0.74, 95% CI 0.59, 0.92, p = 0.008).Conclusion: KLTi adjuvant GP chemotherapy reduces adverse effects in patients with advanced NSCLC. Thus, KLTi might be an effective and safe intervention for NSCLC
Highlights
At present, lung cancer is still one of the major diseases that threaten human health
These studies were evaluated according to the following inclusion criteria: (1) locally advanced or metastatic non-small cell lung cancer (NSCLC) confirmed histologically or cytologically without surgical operations and radiotherapy to the thoracic primary lesion, as well as other traditional Chinese medicine treatment; (2) studies on randomized controlled trials (RCTs); (3) Patients in the experimental group received Kanglaite injection (KLTi) and gemcitabine and cisplatin (GP) combination chemotherapy, and patients in the control group received corresponding conventional GP chemotherapy; (4) The primary outcomes, i.e., primary tumor response rate (CR, partial response (PR), stable disease (SD), progressive disease (PD), etc.) and toxicity, were reported
25 reports were included in the meta-analysis, and 2194 patients who met the inclusion criteria were included, and data was extracted from these trials and used for the qualitative analysis
Summary
Lung cancer is still one of the major diseases that threaten human health. In 2018, the International Agency for Research on Cancer reported that global new cases of cancer reached 18.1 million, out of which 9.6 million are reported to have died. Irrespective of gender, lung cancer is the most commonly diagnosed cancer (11.6% of total cases) and the leading cause of cancer death (18.4% of the total cancer deaths) [1]. In 2020, 19.3 million cases were diagnosed new cases of cancer, with almost 10.0 million deaths according to the International Agency for Research on Cancer. Female breast cancer has surpassed lung cancer for the first time as the most commonly diagnosed cancer. Lung cancer is still the leading cause of cancer-related death, with an estimated 1.8 million deaths (18%). In China, there were 4.57 million new cancer cases in 2020, with lung cancer cases at 0.82 million. The incidence of lung cancer still ranks first: the number of cancer deaths is 3 million, of which lung cancer is as high as 0.71 million [2]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
